There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IGF-I R


Brief Information

Name:Insulin-like growth factor I receptor
Target Synonym:IGF-I receptor,IGF1R,Insulin Like Growth Factor 1 Receptor,Insulin-Like Growth Factor I Receptor,Soluble IGF1R Variant 1,Soluble IGF1R Variant 2,CD221 Antigen,CD221,IGFIR,JTK13,IGFR,Receptor, IGF Type 1,Insulin-Like Growth Factor 1 Receptor,MGC18216
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Human IGF-I R, His TagHuman IGF-I R, His Tag (Cat. No. IGR-H5229) ELISA bioactivity

Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with a linear range of 9-78 ng/mL (QC tested).

Biotinylated Human IGF-I R, His,AvitagBiotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) ELISA bioactivity

Immobilized Biotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with a linear range of 5-156 ng/mL (QC tested).

Synonym Name



The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mecasermin (Ipsen) IGF-1; FK-780; MKN-031 Approved Ipsen Increlex EU Laron Syndrome Ipsen Pharma 2005-08-30 Failure to Thrive; Growth Disorders; Laron Syndrome Details
IGF-1 (Biogen/Pharmacia & Upjohn) Approved Biogen Inc, Pharmacia & Upjohn Igef Sweden Dwarfism null 1994-01-01 Dwarfism Details
Mecasermin (Astellas/OrphanPacific) Approved Astellas Pharma Inc Somazon Japan Dwarfism; Diabetes Mellitus, Lipoatrophic; Growth hormone deficiency null 1994-10-05 Diabetes Mellitus, Lipoatrophic; Dwarfism; Growth hormone deficiency Details
Teprotumumab R-1507; RG-1507; RO-4858696; HZN-001 Approved Genmab, F. Hoffmann-La Roche Ltd Tepezza United States Graves Ophthalmopathy Horizon Therapeutics Ireland 2020-01-21 Graves Ophthalmopathy; Diabetic macular oedema; Sarcoma; Breast Neoplasms; Prostatic Neoplasms; Scleroderma, Diffuse Details
Brigatinib AP-26113 Approved Takeda Pharmaceutical Co Ltd, Ariad Alunbrig Japan Carcinoma, Non-Small-Cell Lung Takeda 2017-04-28 Solid tumours; Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ceritinib LDK-378; NVP-LDK378; NVP-LDK378-NX Approved Novartis Pharma Ag 赞可达, Zykadia Mainland China Carcinoma, Non-Small-Cell Lung Novartis Europharm Ltd 2014-04-29 Stomach Neoplasms; Adenocarcinoma of Lung; Glioblastoma; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Hepatic Insufficiency; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Squamous Cell; Granuloma, Plasma Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VPI-2690B VPI-2690B Phase 2 Clinical University Of North Carolina At Chapel Hill Diabetic Nephropathies Details
124I-CPD-1023-figitumumab 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 Phase 1 Clinical Fusion Pharma Neoplasms Details
BVS-857 BVS-857 Phase 2 Clinical Novartis Pharma Ag Insulin Resistance; Bulbo-Spinal Atrophy, X-Linked Details
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) Phase 1 Clinical Sidney Kimmel Cancer Center Glioma Details
Insulin-Like Growth Factor 1 (Wright State Physicians) Phase 1 Clinical Wright State Physicians Nasolabial fold wrinkles; Sunburn Details
Dalotuzumab h7C-10; MK-0646; F-50-035 Phase 2 Clinical Pierre Fabre Group Rectal Neoplasms; Pancreatic Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Picropodophyllin PPP; AXL-1717; NSC-36407 Phase 2 Clinical Axelar Ab Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
W-0101 (Pierre Fabre Medicament) W-0101 Phase 2 Clinical Pierre Fabre Group Neoplasms Details
BIIB-022 BIIB-022 Phase 1 Clinical Biogen Inc Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Ganitumab AMG-479 Phase 3 Clinical Amgen Inc Sarcoma, Ewing; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lung Neoplasms; Lymphoma; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Intestinal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Colonic Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Solid tumours; Ovarian Neoplasms Details
Conteltinib CT-707; SY-707 Phase 3 Clinical Shouyao Holding (Beijing) Co Ltd, Beijing Sailintai Medicine Technology Co Ltd Carcinoma, Non-Small-Cell Lung Details
CT102 CT-102 Phase 1 Clinical Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences, Hangzhou Tianlong Pharmaceutical Co Ltd Carcinoma, Hepatocellular Details
Mecasermin Rinfabate SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3 Phase 2 Clinical Insmed Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Laron Syndrome; Muscular Dystrophies Details
VB-421 Pierre Fabre Group Details
IGV-001 IGV-001 Phase 2 Clinical Thomas Jefferson University Glioblastoma Details

This web search service is supported by Google Inc.